Real world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.
(2014) In Blood 124(10). p.1570-1577- Abstract
- Peripheral T-cell Lymphomas (PTCLs) are rare lymphomas with mostly poor outcome with current treatment. Addition of etoposide to CHOP and up-front consolidation with autologous stem cell transplantation (autoSCT) have shown promising results, but have never been tested in randomized trials. As a complement to retrospective analyses of clinical trials, we aimed at analyzing prognostic factors and outcome in an unselected, population-based cohort. Through the Swedish Lymphoma Registry we identified 755 PTCL patients diagnosed during a 10-year period. In addition to International Prognostic Index (IPI) factors, male gender was associated with an adverse overall survival (OS) (HR 1.28, p=0.011) and progression-free survival (PFS) (HR 1.26,... (More)
- Peripheral T-cell Lymphomas (PTCLs) are rare lymphomas with mostly poor outcome with current treatment. Addition of etoposide to CHOP and up-front consolidation with autologous stem cell transplantation (autoSCT) have shown promising results, but have never been tested in randomized trials. As a complement to retrospective analyses of clinical trials, we aimed at analyzing prognostic factors and outcome in an unselected, population-based cohort. Through the Swedish Lymphoma Registry we identified 755 PTCL patients diagnosed during a 10-year period. In addition to International Prognostic Index (IPI) factors, male gender was associated with an adverse overall survival (OS) (HR 1.28, p=0.011) and progression-free survival (PFS) (HR 1.26, p=0.014). In an intention-to-treat analysis in 252 nodal PTCL and EATL patients (excluding ALK-positive ALCL), up-front autoSCT was associated with a superior OS (HR 0.58, p=0.004) and PFS (HR 0.56, p=0.002) compared to patients treated without autoSCT. Addition of etoposide to CHOP resulted in superior PFS in patients up to 60 years (HR 0.49, p=0.008). This study is the largest population-based PTCL cohort reported so far and provides important information on outcome in PTCL outside the setting of clinical trials. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4583232
- author
- Ellin, Fredrik LU ; Landström, Jenny ; Jerkeman, Mats LU and Relander, Thomas LU
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Blood
- volume
- 124
- issue
- 10
- pages
- 1570 - 1577
- publisher
- American Society of Hematology
- external identifiers
-
- pmid:25006130
- wos:000342762300011
- scopus:84907051387
- pmid:25006130
- ISSN
- 1528-0020
- DOI
- 10.1182/blood-2014-04-573089
- language
- English
- LU publication?
- yes
- id
- c8298302-4130-4f03-bf68-29e34dd22e32 (old id 4583232)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25006130?dopt=Abstract
- date added to LUP
- 2016-04-01 09:50:06
- date last changed
- 2022-04-19 19:57:04
@article{c8298302-4130-4f03-bf68-29e34dd22e32, abstract = {{Peripheral T-cell Lymphomas (PTCLs) are rare lymphomas with mostly poor outcome with current treatment. Addition of etoposide to CHOP and up-front consolidation with autologous stem cell transplantation (autoSCT) have shown promising results, but have never been tested in randomized trials. As a complement to retrospective analyses of clinical trials, we aimed at analyzing prognostic factors and outcome in an unselected, population-based cohort. Through the Swedish Lymphoma Registry we identified 755 PTCL patients diagnosed during a 10-year period. In addition to International Prognostic Index (IPI) factors, male gender was associated with an adverse overall survival (OS) (HR 1.28, p=0.011) and progression-free survival (PFS) (HR 1.26, p=0.014). In an intention-to-treat analysis in 252 nodal PTCL and EATL patients (excluding ALK-positive ALCL), up-front autoSCT was associated with a superior OS (HR 0.58, p=0.004) and PFS (HR 0.56, p=0.002) compared to patients treated without autoSCT. Addition of etoposide to CHOP resulted in superior PFS in patients up to 60 years (HR 0.49, p=0.008). This study is the largest population-based PTCL cohort reported so far and provides important information on outcome in PTCL outside the setting of clinical trials.}}, author = {{Ellin, Fredrik and Landström, Jenny and Jerkeman, Mats and Relander, Thomas}}, issn = {{1528-0020}}, language = {{eng}}, number = {{10}}, pages = {{1570--1577}}, publisher = {{American Society of Hematology}}, series = {{Blood}}, title = {{Real world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.}}, url = {{http://dx.doi.org/10.1182/blood-2014-04-573089}}, doi = {{10.1182/blood-2014-04-573089}}, volume = {{124}}, year = {{2014}}, }